UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021951
Receipt number R000025315
Scientific Title Efficacy of 4-metre gait speed in the patients with chronic interstitial pneumonia
Date of disclosure of the study information 2016/04/18
Last modified on 2020/11/10 08:27:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of 4-metre gait speed in the patients with chronic interstitial pneumonia

Acronym

4-metre gait speed and chronic interstitial pneumonia

Scientific Title

Efficacy of 4-metre gait speed in the patients with chronic interstitial pneumonia

Scientific Title:Acronym

4-metre gait speed and chronic interstitial pneumonia

Region

Japan


Condition

Condition

Chronic interstitial pneumonia

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the association between 4-metre gait speed and the most used exercise capacity field test, the 6-minute walk test, in patients with chronic interstitial pneumonia. And, to evaluate the determinants and factors influencing 4-metre gait speed in patients with chronic interstitial pneumonia.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

6-minute walk test

Key secondary outcomes

Pulmonary function test, Serological marker, Findings of HRCT, Cardiac ultrasonography, Right heart catheterization, Presence or absence of acute exacerbation, Survival rate at 12 months


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

4-metre gait speed

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who are diagnosed as chronic interstitial pneumonia, as defined by clinical course and the findings of HRCT.

Key exclusion criteria

1. The patients who disagree with involving in this study.
2. The patients had an exacerbation within the preceding 4 weeks.
3. The patients who diagnosed as respiratory disorders other than chronic interstitial pneumonia, malignancy, overt cardiac failure, and hepatic and renal disease.
4. The patients had a predominant neuromuscular limitation to walking.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name SHUJI
Middle name
Last name OH-ISHI

Organization

National Hospital Organization Ibarakihigashi National Hospital

Division name

Department of Respiratory Medicine

Zip code

319-1113

Address

825 Terunuma, Tokai-mura, Naka-gun, Ibaraki 319-1113, Japan

TEL

+81-29-282-1151

Email

ooishi.shuji.dg@mail.hosp.go.jp


Public contact

Name of contact person

1st name SHUJI
Middle name
Last name OH-ISHI

Organization

National Hospital Organization Ibarakihigashi National Hospital

Division name

Department of Respiratory Medicine

Zip code

319-1113

Address

825 Terunuma, Tokai-mura, Naka-gun, Ibaraki 319-1113, Japan

TEL

+81-29-282-1151

Homepage URL


Email

ooishi.shuji.dg@mail.hosp.go.jp


Sponsor or person

Institute

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi National Hospital

Institute

Department

Personal name



Funding Source

Organization

National Hospital Organization Ibarakihigashi National Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Ibarakihigashi National Hospital

Address

825 Terunuma, Tokai-mura, Naka-gun, Ibaraki 319-1113, Japan

Tel

+81292821151

Email

yamano.yoichi.pn@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 04 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

72

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2016 Year 03 Month 01 Day

Date of IRB

2016 Year 02 Month 26 Day

Anticipated trial start date

2016 Year 04 Month 18 Day

Last follow-up date

2021 Year 04 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

At 2018, total of 72 patients joined in this study. 4MGS, 6MWT,and IKE were measured in all participants. There seemed to be a positive correlation between 4MGS and IKE in elderly group (75-years-old or more),whereas such a correlation seemed not to exist in non-elderly group, suggesting that othe factors may influence the reslut of 4MGS in non-elderly group. The above results were presented in 2018 Annual Meeting of European Respiratory Society (Paris). At present, we are following up on the patients enrolled in this study to confirm whether 4MGS is related to the exacerbation of the disease or their prognosis.


Management information

Registered date

2016 Year 04 Month 17 Day

Last modified on

2020 Year 11 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025315


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name